CIK 0001326190 · Non-accelerated filer<br>Smaller reporting company
Altimmune, Inc.
Sign in to watch- Ticker
- ALT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 202726770
- Phone
- 862-457-1450
- Business address
- 350 MOUNT KEMBLE AVENUE, SUITE 1001, MORRISTOWN, NJ, 07960
- Former names
- PHARMATHENE, INC, HEALTHCARE ACQUISITION CORP
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-05-01 | Sohn Catherine A. Director | Grant or award · Stock Options (option to buy) | +48,800 | 48,800 | ||
| 2026-05-01 | Jorkasky Diane Director | Grant or award · Stock Options (option to buy) | +48,800 | 48,800 | ||
| 2026-05-01 | GILL JOHN Director | Grant or award · Stock Options (option to buy) | +48,800 | 48,800 | ||
| 2026-05-01 | SAYARE MITCHEL Director | Grant or award · Stock Options (option to buy) | +48,800 | 48,800 | ||
| 2026-04-06 | GILL JOHN Director | Purchase | +9,200 | $3.41 | $31K | 21,700 |
| 2026-04-01 | Durso Jerome Benedict President and CEO | Purchase | +15,000 | $3.14 | $47K | 47,500 |
| 2026-04-01 | WEAVER GREGORY L Chief Financial Officer | Purchase | +10,000 | $3.15 | $31K | 38,078 |
| 2026-03-06 | Durso Jerome Benedict President and CEO | Purchase | +20,000 | $3.54 | $71K | 32,500 |
| 2026-03-06 | WEAVER GREGORY L Chief Financial Officer | Purchase | +5,000 | $3.54 | $18K | 28,078 |
| 2026-02-26 | Roberts M Scot Chief Scientific Officer | Grant or award · Stock Options (option to buy) | +222,670 | 222,670 | ||
| 2026-02-26 | Roberts M Scot Chief Scientific Officer | Grant or award · Restricted Stock Units | +95,430 | 95,430 | ||
| 2026-02-26 | WEAVER GREGORY L Chief Financial Officer | Grant or award · Stock Options (option to buy) | +259,000 | 259,000 | ||
| 2026-02-26 | WEAVER GREGORY L Chief Financial Officer | Grant or award · Restricted Stock Units | +111,000 | 111,000 | ||
| 2026-02-02 | Roberts M Scot Chief Scientific Officer | Option exercise | +7,775 | 115,153 | ||
| 2026-02-02 | Roberts M Scot Chief Scientific Officer | Shares withheld for taxes | −2,329 | $5.55 | $13K | 112,824 |
| 2026-02-02 | Roberts M Scot Chief Scientific Officer | Option exercise · Restricted Stock Units | −7,775 | 0 | ||
| 2026-01-31 | Roberts M Scot Chief Scientific Officer | Grant or award | +5,567 | $3.07 | $17K | 107,378 |
| 2026-01-31 | Jordt Raymond M Chief Business Officer | Grant or award | +4,571 | $3.07 | $14K | 70,107 |
| 2026-01-31 | Garg Vipin K Director | Grant or award | +6,926 | $3.07 | $21K | 424,519 |
| 2026-01-30 | Roberts M Scot Chief Scientific Officer | Option exercise | +9,275 | 104,670 |
Page 2 of 21 · 403 trades